PDCD1 and non-small cell lung carcinoma: In a trial investigating neoadjuvant sintilimab (anti-PD-1) in patients with resectable non-small cell lung cancer, Tao et al. noted that one patient with a PPR after neoadjuvant sintilimab (anti-PD-1) was classified as having PMD per PERCIST, while MTV and TLG did decrease with 60 and 50%, respectively [12].